|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||21.45 - 21.67|
|52-week range||19.09 - 24.20|
|Beta (5Y monthly)||0.34|
|PE ratio (TTM)||43.25|
|Forward dividend & yield||1.18 (5.47%)|
|Ex-dividend date||19 Feb 2020|
|1y target est||N/A|
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved for administration via an autoinjector. This approval will give healthcare professionals and people living with severe eosinophilic asthma (SEA) or the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) the option for Nucala to be administered outside of a clinical setting by a patient or caregiver after their healthcare professional agrees this approach is appropriate.
LONDON--(BUSINESSWIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple ...